420 with CNW – New Jersey Could Have the Lowest Weed Taxes According to Voter Measure

If everything goes according to plan, New Jersey could be the state with the lowest tax rate for legal weed sales. Voters are expected to vote on a marijuana legalization measure that seeks to allow the state to subject a sales tax of 6.625% on legal weed sales.

All cities allowing the sale of legal weed would be authorized to impose a maximum of 2% transfer tax which would total up to 8.625%. This would still be the lowest tax imposed on legal marijuana sales in the U.S.

According to marijuana analysts, the low taxes would enable legal marijuana to compete with and eventually eradicate the illicit weed market. The period in which New Jersey will be able to start implementing the low rate tax is uncertain.

According to the president of the New Jersey Cannabusiness Association, Scott Rudder, voter approval for recreational weed in the 2020 elections could lead to additional details such as Excise taxes.

Rudder also said that the ballot question should be detailed so that the voters can make an informed decision.

He was of the view that the new regulations would not be implemented until the voters approve the measure, and the tax proposals for the marijuana industry may still be altered.

Rudder  also said other states might legalize marijuana and the desire to have common taxes in the Northeast states where marijuana is legal may force New Jersey to abandon its measure in favor of a collective position agreed upon with neighboring states.

New Jersey would be the only state not imposing an additional tax, such as excise tax, because all the other states that have legalized recreational marijuana impose some excise tax on legal weed sales, which amounts to about 26% when you add both sales and excise tax.

Washington has the highest percentage of tax on legal weed sales, whose average is 43%, while Michigan customers pay the lowest, at 16%.

States where weed is legal allow their cities to impose their additional taxes besides the general sales taxes imposed by the state.

The executive director of the National Organization of Marijuana Laws, Erik Altieri, said that there is a possibility that New Jersey will impose some excise tax by the time the first ounce of legal cannabis is sold. Altieri further noted that the state law would continue to evolve once marijuana is legalized.

Legalization of weed has been a topic for debate in the Legislature for the last two years and the proposed pot taxes have gone through many changes. State Senator Nicholas Scutari introduced a bill in the state Assembly which suggested for an increasing marijuana tax which would begin at 7% and rise to 25% over the next few years. The last bill proposed a $42 flat-rate fee per ounce, which equates to a 12% tax rate. This would ensure a steady source of revenue, even if the market price for marijuana drops.

Scutari said that removing the additional taxes is a sure way of fighting the black market because people would be more inclined to buy the cheap, safe, and high-quality weed from a licensed dispensary instead of purchasing from an illegal dealer.

These proposals seem good on paper, but experts say industry actors like SinglePoint Inc. (OTCQB: SING) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) have learnt that nothing is clearcut in New jersey, so they will only wait to see the final law which is cleared for implementation.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQX: LXRP) Enhanced Technology Shows Rapid Onset of Action in Under 10 Minutes

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced its development of additional enhancements for its industry-leading DehydraTECH(TM) platform that delivers THC onset of action in less than 10 minutes in human pilot testing. According to the update, volunteers in recent human subjective pilot tests reported onset in less than 10 minutes from edibles formulated with this latest DehydraTECH innovation. This enhanced version of the delivery platform shows onset that is roughly twice as fast as traditional DehydraTECH and four to six times faster than generic industry formulations.

To view the full press release, visit http://cnw.fm/G4mY9

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – Lottery Held to Award Recreational Weed Locations to Chicago Applicants

On Friday morning, marijuana companies filled the Chicago City Hall to participate in the first-ever lottery held for awarding recreational marijuana permits.

In the first round, Joel Caltabiano with Cresco Labs got the first pick. The company managed to get a spot at the heart of the city of Chicago, which was coveted by many as it includes an entertainment corridor located near Rive North and the Gold Coast. The central business district (CBD) is highly concentrated with people, hotels, and entertainment joints.

Caltabiano said that being located in the central business district is the best for the company because the area is highly populated. He also noted that the central business district generates most of the city’s tax revenue because it is where most spending is done.

The existing 31 medical dispensaries in Chicago have already been licensed to sell recreational marijuana come January 1 by the state. However, those who participated in the lottery were given a chance to choose a second location in the designated seven districts in Chicago.

Jeremy Unruh, who is from Pharmacann, said that recreational marijuana sales would add to the tax revenue in Chicago. He also noted that it would create new jobs.

Each of the seven districts is allowed a maximum number of seven dispensaries which will be increased to 14 in May. The cap on the number of dispensaries is to make sure that they are uniformly distributed across Chicago, Mayor Lori Lightfoot said.

The downtown spots were snagged up very quickly; however, not all businesses wanted to be at the heart of the action.

The Herbal Care Center medical marijuana dispensary, which neighbors the Illinois Medical District, now has a chance to open a second dispensary in a similar community. Brenda Schiller of The Herbal Care Center said that her company is focused on serving the community instead of the tourists.

The director of business development for Viola Brands, Jamil Taylor, said that he is looking for an opportunity to open an outlet in Illinois because he noticed a lack of diversity in the City Hall during the lottery. Taylor further noted that among the people participating in the lottery, he did not see any people of color or Asians, just people who do not identify with the city of Illinois, which could pose a challenge because of a lack of representation of other races.

The growing recreational marijuana sector will help boost economic development on the South and West sides of Chicago after it becomes legal next year.

Schiller said that the lottery system of awarding permits is a marijuana reform program that further leaves out people who are most affected by the war against drugs.

Before the licensed businesses can get operational, they must host at least one community meeting in their ward.

Experts believe that cannabis companies like Dama Financial and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) are pleased that plans to avail recreational marijuana in Illinois are now in final gear.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

CBDNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Advances Development of Proprietary Drug-Delivery Platform

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, continues to progress the development and patenting of its DehydraTECH(TM) platform. An article discussing the company reads, “The DehydraTECH(TM) drug-delivery platform can be used to deliver substances in edible or in beverage form, and in capsules, pills, syrups and more. Brands in both Canada and the United States have licensed DehydraTECH to make their CBD and cannabis beverages best-in-class. . . . Not only is ingestion a much safer form of drug delivery, but DehydraTECH also delivers the active ingredient of the substance at a rate that is up to five to ten times faster compared with traditional edible products. A 2018 European clinical study demonstrated that 317% more CBD was delivered within half an hour when compared with a positive control of equal strength (http://cnw.fm/2T9z2). The substance being delivered is also rapidly absorbed, which means that people can achieve the effect they are looking for more quickly than was previously the case with edibles. For people looking for quick relief of pain, DehydraTECH is a blessing.”

To view the full article, visit http://cnw.fm/doX61

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Names New Senior Advisor

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, this morning announced the appointment of Gregg Smith as a Senior Advisor for the company. Smith is the founder of Evolution VC Partners (www.EvolutionVCP.com), a New York-based “culture tech” venture investment firm with over 90 portfolio companies. Through his LLC, Smith is acquiring an equity position in LXRP by participating in the company’s recently announced private placement financing of $0.45 units. “I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change. Lexaria’s technology, DehydraTECH(TM), will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis,” Senior Advisor Gregg Smith stated in the news release. “Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences. I expect Lexaria’s technology to play a significant role in that future and I am pleased to advise the management team at Lexaria in defining our leadership strategies.”

To view the full press release, visit http://cnw.fm/jNhW4

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Proprietary Drug-Delivery System Featured in Peer-Reviewed Medical Journal

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug-delivery platforms, recently announced that results of a 2018 clinical study evaluating the use of its proprietary drug-delivery system have been published in the peer-reviewed medical journal Advances in Therapy. (http://cnw.fm/s1Ue7). An article discussing the company reads, “In its report, Advances in Therapy also referenced a second study published recently by a separate group of researchers that evaluated a comparable CBD dose with bioabsorption findings representative of the cannabinoid-edibles industry sector in general. The results indicate that the rate of bioabsorption of the CBD from the competitive 100 mg formulation was virtually nondetectable within 30 minutes of administration, whereas the TurboCBD 90 mg dose delivered as much drug at 30 minutes as the competitor formulation required nearly 2.5 hours to achieve.”

To view the full article, visit http://cnw.fm/VO8gv

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – How to Get Maximum Pain Relief Using Cannabis

When suffering from chronic pain, medical marijuana can help you manage the pain. And since you need to use medical marijuana several times a day, your body may become tolerant of the medicine to the point where your pain does not abate ultimately and leaves you needing more to function normally.

Tolerance of the body to medicine is most seen in patients who have cancer, those living with nerve damage, back injuries, and chronic pain. When the prescription drug becomes tolerated by the bodies of patients suffering from the mentioned ailments, the patients tend to increase the dosages, which could be very harmful to their health as it could lead to addiction or death. However, with marijuana, you cannot be addicted as the compounds used to make medical marijuana are non-psychoactive.

Discussed below are several ways through which you can derive maximum benefits from nature’s best medicine.

  1. Take Your Marijuana Medicine with Something Full of Cholesterol

Research shows that THC binds well to a substance with cholesterol. THC is also fat-soluble; therefore, after taking your marijuana medicine, it is advisable to eat something fatty, such as a slice of bread spread with butter. The CBD binds onto the fat and will be easily distributed throughout the body for maximum pain relief.

  1. Eat a Mango

The terpenes found in mangoes interact well with those found in marijuana, and this action extends the effects of cannabis, keeping the patients relaxed for a more extended period. Patients can therefore eat one immediately before or after taking medical marijuana.

  1. Use Topicals Along with Oral Cannabis Medicine

When ingesting medical marijuana for pain relief, it is advisable also to use topicals to relieve pain on the surface of the places that are in pain. These topical products include salves, creams, or lotions. To get maximum relief, rub them on the parts that are aching, sore, or tense muscles with warm hands, and you will feel the pain abating slowly by slowly.

  1. Switch Up Your Routine

Most marijuana users or patients have that one method that they can swear by that gives them maximum relief. However, switching the method or location may help you get the most of your session. For instance, consummate smokers can switch their smoking devices.

  1. Practice Breathing Techniques

If you are inhaling medical marijuana, take a deep breath, and hold it in to ensure that it reaches your lungs to give a much-needed boost, particularly if you have not smoked for a while. This deep breathing will get the medical cannabis into your bloodstream and relief will follow shortly.

Research is ongoing to identify ways through which cannabis can be amplified to provide relief in small doses. In the meantime, experts believe that cannabis industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and Sproutly Cananda Inc. (CSE: SPR) (OTCQB: SRUTF) (FRA: 38G) wouldn’t object to the options above since they can help patients to use less marijuana to get maximum pain relief.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Applauds FDA Forward-Looking Decision on Reduced Risk Tobacco Format

Global innovator in drug delivery platforms Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) today announced that the Food and Drug Administration (“FDA”), for the first time ever, has authorized the marketing of oral nicotine products through the Modified Risk Tobacco Product pathway. According to the update, this pathway includes product categories that could benefit from Lexaria’s technology. The FDA-authorized product format is in the tobacco pouch category, similar to a mini tea-bag that is held in the mouth from which the nicotine within is absorbed. Unlike chewing tobacco, there is no need to spit. Significantly, because there is no combustion, heating or vaporization of the tobacco pouch during use, as well as FDA-accepted scientific evidence that included long-term epidemiological studies in association with this approval, claims of a lower risk of mouth cancer, stroke, lung disease, heart disease, emphysema and chronic bronchitis than cigarettes are permitted by the FDA. “Lexaria applauds this informed and forward-looking decision by the FDA to recognize improvements in delivery formats that are being made by industry,” Lexaria Bioscience Corp. CEO Chris Bunka said in the news release. “Lexaria realized long ago that DehydraTECH(TM) could empower alternative nicotine product formats and as a result our delivery technology which is already patented in the U.S. and patent pending around the world for enhanced oral nicotine delivery.”

To view the full press releases, visit http://cnw.fm/F4Jh3

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

420 with CNW – 3 Things That Could Characterize the Marijuana 2.0 Launch in Canada

October 17 marked the one-year commemoration of recreational marijuana legalization in Canada. After the legalization of marijuana in 2018, Canadian regulators were fast in developing regulations for marijuana leaf and oil products. However, it took them longer to establish rules for cannabis products such as edibles, cannabis-infused drinks, and concentrates used in vape pens. Implementation of the new regulations led to the opening of a new market, referred to as Cannabis 2.0. Below are the three things that could characterize the Cannabis 2.0 market on the day of their legalization.

  1. No New Product in the Market

Despite the hype surrounding the launch of the cannabis 2.0 market, the event will not be exciting as it was during the launch of the first marijuana market in Canada because no new cannabis derivative product will be introduced in the market.

Licensed marijuana producers are required by law to issue a 60-day notice to Health Canada before selling marijuana products even though the new regulations for cannabis derivatives are already in effect. The consumers will therefore not be able to get their hands on cannabis derivatives until mid-December.

Since the launch of the cannabis 2.0 market comes before the holiday, it will be a while before it can be determined how the market performs and how the holidays affected sales. Reports for the cannabis 2.0 sales for the first quarter of sales will come in February 2020.

  1. Uncertainty Surrounding Cannabis-Infused Beverages And Vaping Products

Analysts and investors will be anxiously waiting for the sales data from the first quarter, which will be more focused on the sale of cannabis-infused beverages and vaping products.

There is much uncertainty surrounding cannabis-infused beverages, and this has forced some companies such as Aurora Cannabis to opt-out of developing cannabis-infused drinks due to the expected low market share of the products, said Cam Battley, the CEO of Aurora Cannabis in the company’s fiscal 2019 Q3 conference in May.

Canopy Growth, in collaboration with Constellation Brands, has developed several types of beverages meant to go up on the shelves later in the year.

Both Aurora and Canopy plan on launching vaping products in the markets, but with the recent scare of vaping-related illness, they are uncertain of how the product will perform and if it will be banned.

  1. Cannabis Edibles Will Attract Huge Sales

Due to the skepticism surrounding vaping products and cannabis-infused beverages, cannabis edibles seem like the safest option to introduce during the launch of cannabis 2.0. Thus, most cannabis producers are planning on producing a variety of cannabis edibles.

For example, Aurora Cannabis plans on producing cannabis chocolate, gummies, and mints. According to Bruce Linton, Canopy Growth plans on creating every type of cannabis edible you can come up with. However, when the former CEO of Canopy, Bruce Linton, made these remarks, the new cannabis regulation had not been finalized by Health Canada.

It is thought that marijuana industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) and IONIC Brands Inc. (CSE: IONC) (OTC: IONKF) would wish to for large market like the U.S. to have a uniform law regulating cannabis in all its forms as is the case in Canada, but that still seems to be far off.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CannabisNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) DehydraTECH Platform Offers Alternative to Traditional Inhalation

Lexaria Bioscience’s (CSE: LXX) (OTCQX: LXRP) innovative DehydraTECH(TM) platform works to deliver chemical compounds to the bloodstream at speeds similar to inhalation methods, offering an alternative to smoking. An article discussing the company further reads, “Lexaria’s noncombustion-based, noninhalation-based delivery method requires no chemicals or additives. . . . ‘We use a patented dehydration synthesis process to combine the nicotine with simple ingredients like sunflower oil in a unique way,’ CEO Chris Bunka told Forbes (http://cnw.fm/HpQm1). ‘It allows for the removal of the bitter taste often associated with nicotine without the need for artificial flavors that are often appealing to children. Moreover, tested in animals in 2018, we proved that DehydraTECH could deliver nicotine to the bloodstream of an animal in as little as two minutes. The fact that it is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.’

To view the full article, visit http://cnw.fm/iT8e4

About Lexaria Bioscience Corp.

Lexaria Bioscience Corp. is a global innovator in drug-delivery platforms. Its patented DehydraTECH(TM) drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com